Lipocine Inc. to Acquire Neuro-Bio Ltd.

TL;DR

Lipocine buying Neuro-Bio to get into neurodegenerative drugs. Deal expected Q3.

AI Summary

Lipocine Inc. announced on June 25, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of privately held company, Neuro-Bio Ltd. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions. This strategic move aims to expand Lipocine's pipeline with Neuro-Bio's novel drug candidates for neurodegenerative diseases.

Why It Matters

This acquisition could significantly expand Lipocine's therapeutic pipeline into the neurodegenerative disease space, potentially offering new treatment options for patients.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, and the success of integrating Neuro-Bio's pipeline into Lipocine's operations carries inherent risks.

Key Players & Entities

• Lipocine Inc. (company) — Acquiring company
• Neuro-Bio Ltd. (company) — Target company
• June 25, 2024 (date) — Announcement date
• third quarter of 2024 (date) — Expected closing period

FAQ

From the Filing

0001493152-24-025037.txt : 20240625 0001493152-24-025037.hdr.sgml : 20240625 20240625081512 ACCESSION NUMBER: 0001493152-24-025037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240625 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241066190 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-06-25 2024-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): June 25, 2024     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐                 Item 8.01 Other Events.   On June 25, 2024, the Company announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic study. The Company is developing LPCN 1154, oral brexanolone, for the treatment of postpartum depression (PPD). The U.S. Food and Drug Administration has agreed with Lipocine’s proposal for a 505(b)(2) NDA filing based on a single pivotal PK bridging study comparing exposure of LPCN 1154 with the approved IV infusion of brexanolone. Intravenous brexanolone is approved based